Estrella Immunopharma ESLA Income Statement (2021-2026)

NASDAQ ESLA
$0.75 +0.01 (+1.11%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter)
2.61M2.61M2.62M0.48M0.08M0.03M3.55M6.38M2.90M1.41M4.66M4.15M0.03M1.40M1.40M
Selling, General & Administrative (Quarter)
0.28M0.43M0.51M1.39M0.95M0.44M0.87M1.42M1.57M0.69M0.88M0.65M0.59M0.89M0.68M
Restructuring Costs (Quarter)
0.13M0.19M0.71M0.04M0.09M0.13M0.08M0.05M0.04M0.10M0.03M0.15M0.05M
Other Operating Expenses (Quarter)
0.01M0.16M0.12M0.40M2.48M5.06M0.29M-0.71M-0.04M-0.09M-0.13M-0.12M-0.05M-0.04M-0.10M-0.03M-0.15M-0.05M
Operating Expenses (Quarter)
0.01M0.16M0.12M0.40M2.89M5.64M8.38M0.29M1.87M1.02M0.47M4.42M7.80M4.43M2.10M5.54M4.80M0.61M2.29M2.08M
Operating Income (Quarter)
-0.11M-0.14M-0.14M-0.42M-2.89M-5.64M-8.38M-0.32M-1.87M-1.02M-0.47M-4.42M-7.80M-4.43M-2.10M-5.54M-4.80M-0.61M-2.30M-2.08M
EBIT (Quarter)
-2.08M
Non-operating items
Non Operating Investment Income (Quarter)
567.00857.000.00M0.06M0.20M0.38M0.11M0.22M
Interest & Investment Income (Quarter)
567.00857.000.00M
Non Operating Income (Quarter)
-0.22M
Net income details
EBT (Quarter)
-2.31M
Tax Provisions (Quarter)
0.08M0.02M0.04M0.00M63.0013.00850.00-2.74M
Profit After Tax (Quarter)
-2.31M
Income from Continuing Operations (Quarter)
-2.31M
Consolidated Net Income (Quarter)
-2.31M
Income towards Parent Company (Quarter)
-2.31M
Net Income towards Common Stockholders (Quarter)
-2.31M
Additional items
EPS (Basic) (Quarter)
-0.05
EPS (Diluted) (Quarter)
-0.05
Shares Outstanding (Quarter)
43.00M
Shares Outstanding (Diluted) (Quarter)
43.00M
Shares Outstanding (Entity) (Quarter)
43.50M
EBITDA (Quarter)
-2.08M
Interest Expenses (Quarter)
0.81M
Tax Rate (Quarter)
-1.43%-0.23%-41.04%-0.02%0.00%0.00%-0.02%447.49%